Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
grade B 13.49 1.50% 0.20
CORT closed up 1.5 percent on Tuesday, September 17, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CORT trend table...

Date Alert Name Type % Chg
Golden Cross Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.50%
Calm After Storm Range Contraction 1.50%
Down 3 Days in a Row Weakness 1.50%
Calm After Storm Range Contraction 1.12%
Stochastic Reached Overbought Strength 0.90%
Upper Bollinger Band Walk Strength 0.90%
Inside Day Range Contraction 0.90%
Overbought Stochastic Strength 0.90%

Older signals for CORT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Pharmaceutical Organ Systems Surgery Disorders Endocrine System Diabetes Mellitus Hormones Depression Cushing's Syndrome Corcept Therapeutics Hyperglycemia Cortisol Endogenous Cushing's Syndrome
Is CORT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.48
52 Week Low 9.14
Average Volume 642,911
200-Day Moving Average 12.0695
50-Day Moving Average 12.1012
20-Day Moving Average 12.817
10-Day Moving Average 13.053
Average True Range 0.4576
ADX 29.49
+DI 28.8116
-DI 13.4246
Chandelier Exit (Long, 3 ATRs ) 12.4672
Chandelier Exit (Short, 3 ATRs ) 13.4928
Upper Bollinger Band 13.6751
Lower Bollinger Band 11.9589
Percent B (%b) 0.89
BandWidth 13.390029
MACD Line 0.3354
MACD Signal Line 0.2897
MACD Histogram 0.0457
Fundamentals Value
Market Cap 1.53 Billion
Num Shares 113 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 67.45
Price-to-Sales 19.04
Price-to-Book 31.30
PEG Ratio 0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.15
Resistance 3 (R3) 14.10 13.83 14.04
Resistance 2 (R2) 13.83 13.66 13.86 14.00
Resistance 1 (R1) 13.66 13.56 13.75 13.71 13.97
Pivot Point 13.39 13.39 13.43 13.42 13.39
Support 1 (S1) 13.22 13.22 13.31 13.27 13.01
Support 2 (S2) 12.95 13.12 12.98 12.98
Support 3 (S3) 12.78 12.95 12.94
Support 4 (S4) 12.83